Community/research information onlyNot FDA/EMA approved

Community protocol · KPV

KPV: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: Lys-Pro-Val · α-MSH fragment

Sources checked: 27 August 2026

Important safety and liability notice

This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

KPV

Is studied preclinically in relation to inflammation, skin and wound repair.

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amounts, timing and cycles

Community/research information only

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amount status

Different amounts circulate online; no regulator-confirmed safe or effective dose exists.

Profile evidence level: preclinical.

Timing

Community claims about time of day, fasting windows or training intervals are not validated clinical standards.

No individual recommendation.

Cycle/duration

Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Reconstitution and U-100 conversion

Reconstitution calculator

For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.

Reconstitution calculator

Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.

Total vial amount (mg)Fluid added (ml)Amount to calculate (µg)

Concentration

3,333.33 µg/ml

Calculated volume

0.06 ml

U-100 units

6 U

Calculated portions per vial

Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.

Mechanism and research questions

Alpha-MSH-derived tripeptide

KPV is classified as “Alpha-MSH-derived tripeptide”. Is studied preclinically in relation to inflammation, skin and wound repair. This describes the investigated pathway but does not validate a community use, amount, route or combination.

Tripeptide fragment

This examines the function of a very short building block made of only three amino acids, comparable to a very short word within a long sentence. Cell signalling or binding behaviour in the lab is typically measured.

Cell migration peptide

This studies how a peptide influences the migration of cells toward an injury site, similar to workers rushing to a construction site. Speed and extent of cell migration are measured in lab models.

Immune-modulating peptide

This studies how a peptide adjusts immune cell activity, similar to a dial that strengthens or dampens the immune response. Immune cell counts and inflammation markers are measured in studies.

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Wound healing anecdotes

People report perceived faster healing of injuries or tendon problems after using certain peptides, usually without a control group or objective measurement. Such individual reports do not establish actual efficacy or safety.

Skin and hair anecdotes

Users exchange personal impressions of skin appearance, wrinkle depth, or hair growth after using cosmetically marketed peptides, usually based on their own photos rather than measurement devices. Such subjective impressions and marketing claims are not proof of a confirmed effect.

Gut health anecdotes

People report subjectively perceived digestive improvements after using gastric-protective or immune-modulating peptides, usually without objective diagnostics. Such self-observations do not establish a confirmed effect on the gut.

Adverse effects and risk boundaries

Many so-called repair peptides lack controlled human studies. Unknown systemic effects, immune reactions, bleeding or vascular effects, and injection-related infection or contamination remain central risks.
Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

Pregnancy, cancer, active infection, coagulation disorders, planned surgery and relevant immune disease call for especially strict professional assessment or avoidance.
Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

There is no validated monitoring schedule for unapproved repair peptides. Clinical findings, signs of inflammation, blood count, liver/kidney function and coagulation may be relevant depending on the question.
Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Preclinical

Research is mostly preclinical; clinical benefit is unconfirmed.

Published evidence

Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.

KPV is a short tripeptide fragment of alpha-MSH, unlike larger melanocortin agents such as afamelanotide.

Storage and stability

The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Comparisons and related profiles

Combinations / stacks

Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Sources and evidence layers

Primary sources and official registries take priority. The community reference is labelled separately.

Primary/technical sourceFDA: 2026 peptide advisory review
Primary/technical sourceFDA — KPV PCAC briefing document
Community referenceKPV — Peptide Dosing Protocols

Back to all 64 profiles Open scientific atlas profile